Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies Isenberg JS; Martin-Manso G; Maxhimer JB; Roberts DDNat Rev Cancer 2009[Mar]; 9 (3): 182-94In addition to long-term regulation of angiogenesis, angiogenic growth factor signalling through nitric oxide (NO) acutely controls blood flow and haemostasis. Inhibition of this pathway may account for the hypertensive and pro-thrombotic side effects of the vascular endothelial growth factor antagonists that are currently used for cancer treatment. The first identified endogenous angiogenesis inhibitor, thrombospondin 1, also controls tissue perfusion, haemostasis and radiosensitivity by antagonizing NO signalling. We examine the role of these and other emerging activities of thrombospondin 1 in cancer. Clarifying how endogenous and therapeutic angiogenesis inhibitors regulate vascular NO signalling could facilitate development of more selective inhibitors.|*Signal Transduction[MESH]|Angiogenesis Inhibitors/*therapeutic use[MESH]|Animals[MESH]|CD36 Antigens/physiology[MESH]|Cyclic GMP/physiology[MESH]|Hemostasis[MESH]|Humans[MESH]|Neoplasms/etiology[MESH]|Nitric Oxide/*physiology[MESH]|Radiation Tolerance[MESH]|Regional Blood Flow[MESH]|Thrombospondin 1/*physiology[MESH] |